Track Botanix Pharmaceuticals Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Botanix Pharmaceuticals Limited BOT.AX Open Botanix Pharmaceuticals Limited in new tab

0.0270 AUD
EPS
-0.05
P/B
1.00
ROE
-121.11
Beta
0.83
Target Price
0.49 AUD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 28, 2026
EPS-0.05
Book Value0.03
Price to Book1.00
Debt/Equity2.00
% Insiders9.637%
Growth
Revenue Growth42.71%
Estimates
Forward P/E-2.08
Forward EPS-0.01
Target Mean Price0.49

DCF Valuation

Tweak assumptions to recompute fair value for Botanix Pharmaceuticals Limited (BOT.AX)
Currency: AUD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Botanix Pharmaceuticals Limited Logo Botanix Pharmaceuticals Limited Analysis (BOT.AX)

Australia Health Care Official Website Stock

Is Botanix Pharmaceuticals Limited a good investment? Botanix Pharmaceuticals Limited (BOT.AX) is currently trading at 0.0270 AUD. Market analysts have a consensus price target of 0.49 AUD. This suggests a potential upside from current levels.

Earnings Schedule: Botanix Pharmaceuticals Limited is expected to release its next earnings report on Aug. 28, 2026. The market consensus estimate for Forward EPS is -0.01.

Investor FAQ

Does Botanix Pharmaceuticals Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is Botanix Pharmaceuticals Limited?

Botanix Pharmaceuticals Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 28, 2026. The company currently has a trailing EPS of -0.05.

Company Profile

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.

Exchange Ticker
ASX (Australia) BOT.AX
PNK (United States) BXPHF
Historical Dividends
Year Total Dividends
1996 0.10 AUD
1995 0.08 AUD
1994 0.08 AUD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion